Rockefeller Financial Services Inc. lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 341,289 shares of the life sciences company’s stock after selling 21,704 shares during the period. Rockefeller Financial Services Inc. owned about 0.23% of Illumina worth $59,220,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the company. Advocacy Wealth Management Services LLC purchased a new stake in Illumina during the first quarter worth $102,000. Gemmer Asset Management LLC increased its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the period. Advisory Services Network LLC purchased a new stake in Illumina during the first quarter worth $117,000. Patten Group Inc. increased its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the period. Finally, NN Investment Partners Holdings N.V. increased its stake in Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after buying an additional 100 shares during the period. Institutional investors and hedge funds own 93.75% of the company’s stock.
Illumina, Inc. (NASDAQ ILMN) traded up 0.34% during trading on Friday, hitting $174.92. 622,607 shares of the stock were exchanged. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $189.48. The stock has a 50 day moving average price of $174.72 and a 200-day moving average price of $171.38. The firm has a market capitalization of $25.54 billion, a PE ratio of 35.40 and a beta of 0.84.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. The business had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. Illumina’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.71 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post $3.63 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://stocknewstimes.com/2017/07/28/illumina-inc-nasdaqilmn-shares-sold-by-rockefeller-financial-services-inc-updated.html.
A number of equities research analysts have weighed in on ILMN shares. TheStreet upgraded Illumina from a “c+” rating to a “b” rating in a research report on Thursday, April 6th. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 target price for the company. in a research report on Tuesday, April 11th. Bank of America Corporation upped their target price on Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Leerink Swann restated a “buy” rating on shares of Illumina in a research report on Wednesday, April 5th. Finally, Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $191.00 target price for the company in a research report on Tuesday, April 4th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $167.02.
In other Illumina news, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $170.77, for a total value of $2,561,550.00. Following the completion of the transaction, the director now directly owns 534,176 shares in the company, valued at approximately $91,221,235.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the completion of the sale, the senior vice president now directly owns 10,936 shares in the company, valued at $2,045,797.52. The disclosure for this sale can be found here. Insiders sold a total of 125,248 shares of company stock valued at $22,281,673 over the last 90 days. Corporate insiders own 1.60% of the company’s stock.
About Illumina
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
